NeuroSense Therapeutics Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About NeuroSense Therapeutics
Pharmaceutical Preparations, SIC 2834
NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurodegenerative diseases. Its lead product candidate is PrimeC, a novel therapeutic designed to treat Amyotrophic Lateral Sclerosis (ALS). In addition to PrimeC, the company maintains research programs exploring preclinical product candidates for other neurodegenerative conditions. As a development-stage entity without approved commercial products, NeuroSense does not yet serve commercial customers or patients directly, with its operational activities centering on preclinical studies and clinical trials.
The company operates primarily through research, development, and clinical evaluation efforts targeting regulatory approval in jurisdictions such as the United States and Canada. NeuroSense Therapeutics conducts its business operations and clinical trial coordination in collaboration with third-party clinical research organizations and contractors. The company is incorporated in Israel and maintains its principal executive offices and headquarters in Herzliya, Israel.
Summary of the business section of NeuroSense Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NeuroSense Therapeutics Ltd.
- Founded
- 2017
- Headquarters
- Herzliya, L3
- Address
- 11 Hamenofim St., Building B 4672562
- Phone
- 972-9-9531142
- Website
- neurosense-tx.com
- Employees
- 20, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Somekh Chaikin, Tel Aviv, Israel
Stock & identifiers
- Ticker
- NRSN
- Other tickers
- NRSNW
- Exchange
- Nasdaq
- IPO date
- Dec 10, 2021
- Shares outstanding
- 33M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Sep 25, 2026; 1-for-20 reverse, Sep 14, 2026
- SEC CIK
- 1875091
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alon Ben-Noon | Chief Executive Officer | 4,534,233 |
| Or Eisenberg | Chief Financial Officer | 1,504,050 |
| Niva Russek-Blum | Chief Technology Officer | 39,881 |
| Hagit Binder | General Manager | 521,806 |
| Ferenc Tracik | Chief Medical Officer | 189,618 |
| Revital Mandil-Levin | Director | 52,526 |
| Mark Leuchtenberger | Director | 128,000 |
| Cary J. Claiborne | Director | 60,000 |
| Roy Golan | Director | 60,000 |
| Christine A. Pellizzari | Director | 99,898 |
Employees
Headcount reported in annual reports
“A bonus for certain employees in the form of 100,000 and 60,000 RSUs. The RSUs vest on a quarterly basis over one year following the grant and on an annual basis over three years following the grant, respectively. … F- 20”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 10, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 18, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |